stoxline Quote Chart Rank Option Currency Glossary
  
Seres Therapeutics, Inc. (MCRB)
7.055  0.1 (1.44%)    05-09 16:00
Open: 6.9
High: 7.2385
Volume: 129,693
  
Pre. Close: 6.955
Low: 6.64
Market Cap: 62(M)
Technical analysis
2025-05-10 10:04:06 AM
Short term     
Mid term     
Targets 6-month :  13.06 1-year :  16.35
Resists First :  11.18 Second :  14
Pivot price 8.8
Supports First :  6.63 Second :  5.52
MAs MA(5) :  8.01 MA(20) :  9.09
MA(100) :  14.17 MA(250) :  16.49
MACD MACD :  -1.2 Signal :  -1.2
%K %D K(14,3) :  15 D(3) :  22.4
RSI RSI(14): 33.6
52-week High :  30.6 Low :  0.76
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MCRB ] has closed above bottom band by 5.1%. Bollinger Bands are 34.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.26 - 7.3 7.3 - 7.35
Low: 6.53 - 6.59 6.59 - 6.64
Close: 6.96 - 7.06 7.06 - 7.14
Company Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 08 May 2025
Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com

Thu, 08 May 2025
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey

Thu, 08 May 2025
Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour

Thu, 08 May 2025
Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks

Wed, 07 May 2025
Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks

Wed, 07 May 2025
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 9 (M)
Shares Float 6 (M)
Held by Insiders 13 (%)
Held by Institutions 36.2 (%)
Shares Short 763 (K)
Shares Short P.Month 836 (K)
Stock Financials
EPS -16.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.59
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -30.5 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -1.67
Sales Per Share 0
EBITDA (p.s.) -13.29
Qtrly Earnings Growth 0 %
Operating Cash Flow -149 (M)
Levered Free Cash Flow -60 (M)
Stock Valuations
PE Ratio -0.44
PEG Ratio 0
Price to Book value 4.43
Price to Sales 0
Price to Cash Flow -0.42
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android